Mind Medicine (MindMed) Inc. (MNMD) News
Filter MNMD News Items
MNMD News Results
|Loading, please wait...|
MNMD News Highlights
- MNMD's 30 day story count now stands at 17.
- Over the past 16 days, MNMD's stories per day has been in a clear downtrend, falling by about 1.20 per 4 days.
- The most mentioned tickers in articles about MNMD are NEO, CHGG and HOG.
Latest MNMD News From Around the Web
Below are the latest news stories about Mind Medicine (MindMed) Inc that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company's issued and outstanding multiple voting shares (the "Multiple Voting Shares") will undergo a mandatory conversion into subordinate voting shares (the "Subordinate Voting Shares") (the "Conversion"), in accordance with the Company's Articles. The Co
GAINERS: Mind Medicine (NASDAQ:
The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.
Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment.
Thinking about buying stock in Velodyne Lidar, Chegg, Louisiana-Pacific Corp, Harley-Davidson, or Mind Medicine?
NEW YORK , Feb. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLDR, CHGG, LPX, HOG, and MNMD. … Full story available on Benzinga.com
TORONTO , Feb. 7, 2022 /CNW/ - Trading resumes in: Company: MIND MEDICINE (MINDMED) INC. NEO Exchange Symbol: MMED All Issues: No Resumption (ET): 3:26:19 PM IIROC can make Full story available on Benzinga.com
The following issues have been halted by IIROC:
Mind Medicine (MNMD) is trading ~7% higher in the pre-market after announcing that the FDA cleared its Investigational New Drug ((IND)) application, allowing the company to start a Phase…
Investment company Busey Wealth Management (Current Portfolio) buys Broadcom Inc, Canadian Pacific Railway, Globe Life Inc, BTC iShares U.S.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.